The Danish pharmaceutical company Novo Nordisk $NOVO B (-6,06%) has suffered a setback in the development of an Alzheimer's drug. The tested active substance semaglutide, also the basis of the well-known weight loss injection Wegovy, did not achieve its main objective in a decisive phase 3 study with an older, orally administered version: to slow the progression of cognitive decline in Alzheimer's patients, as the company announced on Monday